Immune globulin adjusted body weight dosing program beginning August 1, 2021
Since this program is voluntary, the decision to participate will not affect the final decision on the prior authorization.
Reviews for the immune globulin medications will continue to be administered by IngenioRx® as these will specifically target specialty non-oncology indications.
As part of the prior authorization process, providers may be asked the following questions:
- Whether the suggested use of AdjBW and change in dose is clinically acceptable
- Clinical reasoning if the dose change (using AdjBW) is not appropriate
Providers can view prior authorization requirements for Anthem members on the Medical Policy & Clinical UM Guidelines page at anthem.com.
Providers should continue to verify eligibility and benefits for all members prior to rendering services.
If you have questions, please call the Provider Service phone number on the back of the member’s ID card.
August 2021 Anthem Provider News - Indiana